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Abstract
Albright hereditary osteodystrophy (AHO) is characterized by short stature, brachydactyly, and often heterotopic
ossifications that are typically subcutaneous. Subcutaneous ossifications (SCO) cause considerable morbidity in AHO with no
effective treatment. AHO is caused by heterozygous inactivating mutations in those GNAS exons encoding the a-subunit of
the stimulatory G protein (Gas). When inherited maternally, these mutations are associated with obesity, cognitive
impairment, and resistance to certain hormones that mediate their actions through G protein-coupled receptors, a
condition termed pseudohypoparathyroidism type 1a (PHP1a). When inherited paternally, GNAS mutations cause only AHO
but not hormonal resistance, termed pseudopseudohypoparathyroidism (PPHP). Mice with targeted disruption of exon 1 of
Gnas (Gnas
E12/+) replicate human PHP1a or PPHP phenotypically and hormonally. However, SCO have not yet been
reported in Gnas
E1+/2 mice, at least not those that had been analyzed by us up to 3 months of age. Here we now show that
Gnas
E12/+ animals develop SCO over time. The ossified lesions increase in number and size and are uniformly detected in
adult mice by one year of age. They are located in both the dermis, often in perifollicular areas, and the subcutis. These
lesions are particularly prominent in skin prone to injury or pressure. The SCO comprise mature bone with evidence of
mineral deposition and bone marrow elements. Superficial localization was confirmed by radiographic and computerized
tomographic imaging. In situ hybridization of SCO lesions were positive for both osteonectin and osteopontin. Notably, the
ossifications were much more extensive in males than females. Because Gnas
E12/+ mice develop SCO features that are
similar to those observed in AHO patients, these animals provide a model system suitable for investigating pathogenic
mechanisms involved in SCO formation and for developing novel therapeutics for heterotopic bone formation. Moreover,
these mice provide a model with which to investigate the regulatory mechanisms of bone formation.
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Introduction
Mutations in GNAS exons that encode the alpha-subunit of the
stimulatory G protein (Gas) lead to Albright Hereditary Osteo-
dystrophy (AHO), which is characterized by brachydactyly,
brachymetacarpia, short stature, and frequently subcutaneous
ossifications (SCO), i.e. heterotopic bone formation [1–4]. In some
cases, ossifications are limited to the dermis and subcutaneous
tissue whereas in others the ossifications are deeply invasive [2,4].
It is the only monogenic condition in which de novo ossifications
form subcutaneously and remain limited to the skin, but both the
etiology of the ossifications and their extent of invasiveness are as
yet a mystery. When GNAS mutations are inherited maternally,
AHO is associated with the development of pseudohypoparathy-
roidism type 1a (PHP1a), i.e. PTH-resistance leading to hypocal-
cemia and hyperphosphatemia, resistance to several other peptide
hormones that mediate their actions through G protein-coupled
receptors, as well as obesity and various degrees of cognitive
impairment. When the same mutations are inherited paternally,
affected individuals develop AHO, including SCO, in the absence
of hormonal resistance and obesity, termed pseudopseudohypo-
parathyroidism (PPHP). Brachydactyly and heterotopic ossifica-
tions occur in AHO regardless of the parent of origin of the GNAS
mutation and most likely reflect the effect of haploinsufficiency in
cells that normally express Gas from both GNAS alleles (For
review, see [3,5–8]). Dependence on the parental origin of the
mutant GNAS allele has been found to be secondary to tissue-
specific imprinting of Gas expression based on research conducted
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patients with GNAS mutations, SCO can appear without other
features of AHO and is therefore termed osteoma cutis, but may
later evolve into AHO with or without its associated hormonal
abnormalities [20]. Removal of the skin lesions is often followed by
a recurrence. The reason for SCO developing only in some
patients is not well understood, although SCO tend to form in
areas of persistent pressure and worsen with time [3]. Even though
loss of G protein-signaling from one parental allele seems to be
required for the formation of ossified areas, the underlying
mechanisms are incompletely understood.
Interestingly, an entity termed progressive osseous heteroplasia
(POH), which occurs predominantly secondary to paternal
inheritance of GNAS mutations with absence of other AHO
features [2,21,22], may well represent an extreme variant of AHO
involving heterotopic bone formation. The ossifications that occur
in POH can be very invasive and may extend below the dermis
into the fat and muscle layers [2,4], thereby leading to skeletal
deformities, which can markedly limit a patient’s mobility and can
be the cause of additional morbidity.
It is unknown why the paternal inheritance of a GNAS mutation
leads to PPHP in some cases and to POH in others. In addition, it
is not known why the ossifications in AHO remain confined to the
subcutaneous tissue, yet can be invasive in POH. Studying AHO
and POH may thus provide unique opportunities to gain novel
insights into the mechanism leading to the formation of
ossifications as well as the mechanism that controls the propensity
of the ossifications to become invasive.
Targeted, heterozygous disruption of exon 1 of the Gnas gene
(Gnas
E12/+) provided a mouse model of AHO, which recapitulated
some of the features of the human disease [10,23,24]. However,
we did not observe heterotopic bone formation in the group of
Gnas
E12/+ mice that was examined by palpation or radiographic
studies during the first 3 months of life [10]. However, because
AHO patients typically show increasing and worsening ossifica-
tions with time [3], we therefore evaluated older Gnas
E12/+ mice
for the development of SCO and found extensive ossifications
[24]. This provided further evidence for the conclusion that our
mouse model of AHO replicates the human disease closely, both
phenotypically and hormonally [10]. The objective for this study
was to further characterize in Gnas
E12/+ mice the ossifications and
the timing of their progression to determine whether these animals
could provide a system in which to examine the mechanisms
leading to heterotopic bone formation. Our ultimate goal would
be to utilize this mouse model to find possible methods for the
prevention and treatment of heterotopic bone formation, a source
of great morbidity in patients with AHO and POH. Additionally,
these mice provide a model system with which to investigate the
fundamental regulatory mechanisms of bone formation.
Materials and Methods
Ethics statement
Tissues were obtained from one human subject with AHO
following a protocol approved by the Institutional Review Board
(IRB) of the Johns Hopkins Medical Institutions with written
informed consent obtained (by E.L.G.-L.). The protocol
(#MO10M188) for all mouse studies was approved by the Johns
Hopkins University School of Medicine Animal Care and Use
Committee and followed federal (NIH) guidelines for the humane
and appropriate care of laboratory animals. The animals were
housed in cages on ventilated racks in centralized mouse facilities




E12/+ mice were generated by targeted disruption of
exon 1, as described previously [10,23]. All mice that carried a
mutant maternal allele are hereafter referred to as Gnas
E12m/+
mice and those with a mutant paternal allele as Gnas
E1+/2p. Wild-
type mice are referred to as WT. The mice examined in these
studies were maintained on a pure 129SvEv background [10] with
ad libitum feeding of Prolab RMH2500 mouse chow, which
contains 0.95% calcium and 0.96% phosphate, and ad libitum
water.
Histology
Tissues were obtained from one human subject with AHO and
fixed in formalin, demineralized in formic acid solution, embedded
in paraffin, sectioned at 5 mm and stained with H&E for
histological examination. For mice, the skin was removed intact
and was flattened by pinning to index card paper during fixation
for 48 hours in cold 4% paraformaldehyde. Skin tissue remained
attached to the card and was transferred to 70% ethanol. Skin
sections approximately 1–2 mm thick and 2 cm long were cut for
embedding, parallel to the direction of the hair from the dorsum,
ventrum, and limbs, cutting through any bony foci that were
noted. The sections were positioned with the cut surface down and
placed into cassettes. In order to section skin on the foot pads, the
extremities were disarticulated at the carpus and tarsus joints with
the skin in place, fixed in cold 4% paraformaldehyde for 48 hours
and decalcified in cold 0.5 M EDTA for 7–10 days. One to two
mm thick longitudinal sections from each of the feet were placed
into cassettes for embedding. The tissues were embedded in
paraffin using routine automatic processing and several 5 mM
serial sections made and stained for H&E, Alizarin Red, or von
Kossa following routine protocols. Unstained sections were used
for non-isotopic in situ hybridization. Images were captured using
an upright Zeiss Axioskope with a Nikon 1200 DMX digital
camera.
In situ hybridization
In situ hybridization was performed on sections as described
[25,26] with modifications. Briefly, all slide racks, buckets, and
containers were treated with DEPC water (1:1000) before starting.
The mouse osteonectin and osteopontin cDNA fragments were
amplified by PCR using specific primers (Osteopontin Forward: 59
GATGATGACGATGGAGAC-39; Osteopontin-Reverse: 59-
TGCAAAGTAAGGAACTGTG-39; Osteonectin Forward: 59-
GGTGCTAACATAGATTTAACTG-39; Osteonectin Reverse:
59-AGCCCAATTGCAGTTGAG-39) and each was cloned into
the pCRHII-TOPOH Vector. The plasmids were linearized, and
antisense and sense single-stranded RNA probes were generated
using T7 and SP6 RNA polymerase with digoxigenin (Roche).
Riboprobes (500–600 bp in length) for osteonectin and osteopon-
tin were tested and selected based on the best signal to noise ratio.
Sections were deparaffinized, treated with Proteinase K, rinsed,
and hybridized with the digoxigenin-labeled riboprobes at 55uC
overnight. The next day, slides were washed, blocked, and
incubated with HRP-anti-DIG antibody (Dako) for 45 minutes,
washed, then incubated with biotinyl-tyramide (Dako) for
8 minutes, washed, and detected with BCIP/Blue (Sigma).
Radiographic analyses
Three, six, nine, and twelve month old mice were given
intraperitoneal injections of 0.2–0.5 mL of 20 mg/mL Avertin
[2,2,2,-tribromoethanol (Sigma-Aldrich, St. Louis, MO)] dissolved
in tert-amyl alcohol (Sigma-Aldrich)]. Mice were placed in
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21755Figure 1. Analysis of human subcutaneous ossification. A) Surgically removed area of ossification from a 20 year old male AHO (2p/+) patient
with a documented GNAS mutation. The site contained multiple irregular firm masses 0.5–4 cm in length with branching extensions from a central
mass. B) Ossified lesion in Figure 1A stained with hematoxylin and eosin. The lesion is composed of mature bone with frequent central bone marrow
elements. Scale bar=50 mm.
doi:10.1371/journal.pone.0021755.g001
Figure 2. Analyses of subcutaneous ossifications in mice. A) feet of a Gnas 2m/+ male compared to WT (wild type) male at 12 months of age;
B) ear of a Gnas 2m/+ male at 12 months of age with nodular subcutaneous ossifications; C) X-ray of Gnas 2m/+ male at 3 months of age showing
occasional subcutaneous ossifications; D) X-ray of 12 month 2m/+ obese male with extensive subcutaneous ossifications.
doi:10.1371/journal.pone.0021755.g002
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Wheeling, IL) and exposed to 20–28 kV for 15 seconds.
Computerized Tomography (CT) scans
Three month and 12 month old mice were anesthetized with
0.5–1.0% IsoFlo (isoflurane, USP; Abbott Laboratories, North
Chicago, IL) delivered via Medical E oxygen at 1 L/min. Mice
were scanned using X-SPECT (Gamma Medica-Ideas, North-
ridge, California) with 512 projections over 10 minutes and with a
slice thickness of 0.19 mm. Images were reconstructed using
COBRA (Exxim Computing Corporation, Pleasanton, CA).
Reconstructed raw images were then analyzed for heterotopic
ossifications using Image J software v.1.4.3.67 (1993–2006, Broken
Symmetry Soft).
Results
Analysis of Human SCO
Subcutaneous ossifications are a common complication of AHO
that can lead to great pain and extensive lesions in patients with this
condition. One such site of ossification was surgically resected from
the subcutis of the lower leg of a 20 year old male AHO (2p/+)
Figure 3. Whole body computerized tomographic (CT) images reveal subcutaneous ossifications. CT scans of 12 month (A–D) and 3
month (E, F) male and female mice with heterozygous targeted disruption of exon 1 in the Gnas gene. Arrows indicate a subset of the subcutaneous
ossifications. A) male 2m/+,. B) female 2m/+. C) male +/2p. D) female +/2p. E) male 2m/+. F) female 2m/+.
doi:10.1371/journal.pone.0021755.g003
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lAAGT) (informed consent obtained) [27]. The site contained
multiple irregular firm masses 0.5–4 cm in length often with
branching, tapered extensions from a central mass (Fig. 1A).
Histologically the masses were composed of mature bone frequently
containing central bone marrow elements (Fig. 1B).
Gnas
E12/+ mice develop SCO over time
Dermal and subcutaneous ossifications were not palpated or
visualized in 104 Gnas
E12/+ mice at 3 months of age. We therefore
performed physical examinations on 67 older Gnas
E12/+ animals
to search for subcutaneous ossifications. Examination of these 12
month old Gnas
E12/+ mice [39 males (21 2m/+,1 8+/2p) and 28
Table 1. Radiographic Imaging of Subcutaneous Ossifications Over Time.
Radiographic Imaging of Subcutaneous Ossifications
3M o 6M o 9M o 12 Mo
Number of mice with ossifications/total mice examined (# of foci*)
Male 2m/+ 1/13 (1+) 6/13 (2+) 12/12 (3+) 12/12 (4+)
Female 2m/+ 0/13 (1+) 1/13 (1+) 3/12 (1+) 3/11 (2+)
Male +/2p 1/16 (1+) 8/16 (2+) 15/15 (3+) 15/15 (4+)






Figure 4. Radiographic analyses of mice reveal multiple subcutaneous ossifications. X-rays of 12 month +/2p and WT mice. A) 12 month
+/2p female with no ossifications visualized; B) 12 month +/2p male, inset and arrows demonstrate areas consistent with ossifications; C) 12 month
WT without areas of ossifications.
doi:10.1371/journal.pone.0021755.g004
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erosive footpad lesions in 56 of these mice [38 males (20 2m/+,1 8
+/2p) and 18 females (7 2m/+,1 1+/2p)] (Fig. 2A). Palpable
subcutaneous nodules were present in 30 mice, all males (15 2m/+
and 15 +/2p). Occasional mice had nodular subcutaneous ear
lesions,which were always near the site of ear tags [6 males (42m/+,
2 +/2p) and 1 female (2m/+)] (Fig. 2B). Similar lesions were not
found in 52 WT mice at the age of 12 months (30 males, 22 females).
Figure 5. Histological examination of the skin reveals bone formation. Histological examination of the skin from the trunk (Fig. 5B,5D,5F,5H)
and feet (Fig. 5A,5C,5E,5G) of male and female 2m/+ and 2p/+ mice reveal mineralized bone formation often associated with a dense eosinophilic
osteoid-like matrix in the dermis and perifollicular areas. No abnormalities were observed in WT mice. Occasional osteoid-like material was present
without bone, immediately adjacent to hair follicles, especially in female mice which had milder lesions (Fig. 5F, 5H). Subcutaneous bone frequently
contained central bone marrow elements making it histologically indistinguishable from mature skeletal bone (Fig. 5B, 5D). Scale bars=50 mm.
doi:10.1371/journal.pone.0021755.g005
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that occur in AHO patients based on examination of these lesions
in many patients with this disorder (E.L.G.-L., not shown). As in
the Gnas
E12/+ mice, the lesions in humans most commonly occur
under the skin, especially of the feet, as well as other areas of
pressure/trauma. These ossifications were also, occasionally,
localized dermally.
Radiographic analyses of 60 mice revealed multiple small
densities in the subcutis consistent with mineralized foci that were
rare in 3 month old mice and when present, were small with
limited radiopacity (Fig. 2C). However, multiple foci were found in
all 12 month old mice with targeted disruption of Gnas (Fig. 2D).
No densities were detected in WT mice. (Details described below.)
Whole body computerized tomographic (CT) images revealed
subcutaneous densities that were easily detectable in all 12 month-old
Gnas
E12/+ mice examined (male 2m/+;f e m a l e2m/+;m a l e+/2p;
female +/2p) (Fig. 3A–D). Consistent with the radiographic studies,
no densities by CT were found in WT mice. The CT images
confirmed localization of the ossifications to the subcutaneous layer.
Only one 3 month old mouse of each gender and genotype (out of
four examined for each) had a few very small subcutaneous densities
(Fig. 3E, 3F). The X-ray and CT findings thus demonstrated that
subcutaneous ossifications occurred with maternally and paternally
inherited alleles of both genders, occasionally at 3 months of age and
in all mice by 12 months of age; at 12 months of age the ossifications
were much more noticeable.
After this observation, the natural history of the evolution of the
ossifications was followed in a large number of mice of both genders
and both genotypes by serial radiographic analyses (2m/+ and
+/2p) at 3,6, 9,and 12 months(Table 1).With progression of time,
more ossifications appeared in both genders. However, the female
micehad far less ossificationsat all timespoints examined compared
to themales (Fig.4).In addition, at 12months the lesionsweremore
severe in males than in females for both maternally and paternally
inherited alleles upon histologic analyses (described below).
Heterotopic ossifications were not present in any WT mice.
Histologic analyses of murine SCO
Histological examination of the skin from the trunk (Fig. 5B, 5D,
5F, 5H) and feet (Fig. 5A, 5C, 5E,5G) of male and female 2m/+and
2p/+ mice revealed mineralized bone formation often associated
with a dense eosinophilic osteoid-like matrix in the dermis and
perifollicular areas. No abnormalities were present in WT mice.
Occasionally a small amount of osteoid-like material was present
without bone, immediately adjacent to hair follicles, especially in
female mice that had milder lesions (Fig. 5F, 5H). The less frequent
a n dm i l d e rl e s i o n si nf e m a l e sv e r s u sm a l e sn o t e dh i s t o l o g i c a l l yw e r e
consistent with radiographic findings (Fig. 4). Subcutaneous bone
frequently contained central bone marrow elements making it
histologically indistinguishable from mature bone (Fig. 5B, 5D).
The dermis of 3 month old 2m/+ and +/2p male and female
mice had no heterotopic bone formation in the sections of dermis
Figure 6. The dermis and subcutis of 3 month old male mice with heterozygous targeted disruption of exon 1 of the Gnas gene. The
2m/+ and +/2p male and female mice had no heterotopic bone formation. However, there were subtle lesions in the dermis of both 2m/+ and
+/2p male mice that comprised widely scattered plaque-like areas with pale collagen and increased cellularity in periadnexal areas of the reticular
dermis. A) 2m/+ male; B) +/2p male; Scale bar=50 mm.
doi:10.1371/journal.pone.0021755.g006
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2m/+ and +/2p male mice (Fig. 6), which contained occasional
plaque-like areas in the superficial dermis with increased cellularity
and a light amphophilic matrix. The lesions were widely scattered
with pale collagen and increased cellularity most pronounced in
periadnexal areas of the reticular dermis. These may represent
mild or early lesions that precede subcutaneous ossification as
these plaque-like areas were not present in sections examined from
3 month old wild type mice.
Subcutaneous ossifications are mineralized and express
osteoblast markers
Special stains of subcutaneous bone lesions in 12 month old
Gnas
E12/+ mice using Alizarin Red and von Kossa confirmed that
the subcutaneous bone osteoid was indeed mineralized (Fig. 7A–
C). Sites of subcutaneous ossification (Fig. 7D) also contained cells
along the edges of the areas of ossification that expressed
osteopontin and osteonectin, consistent with osteoblastic differen-
tiation, as demonstrated by in situ hybridization (Fig. 7E, 7F).
Upon examination of histologic sections, the SCO appeared to
originate in the perifollicular areas, emanating near the hair follicle
both with hematoxylin and eosin staining (Fig. 8A) as well as
Alizarin Red staining. The Alizarin Red staining encircled the hair
follicles in some areas (Fig. 8B). Areas of mineralized bone were
often associated with a dense eosinophilic osteoid-like matrix in the
dermis and perifollicular areas (Fig. 5B, 5D, 5F, 5H). Occasionally
a small amount of osteoid-like material was present without bone,
immediately adjacent to hair follicles.
Discussion
Our mouse model of AHO replicates the human disorder
closely, both phenotypically and hormonally [10], and is the first
mouse model to exhibit SCO. Although mice with chondrocyte-
specific ablation of Gnas exhibit ectopic cartilage formation within
the metaphyseal region of the tibia [28] and those with targeted
heterozygous disruption of exon 2 of Gnas (Gnas
E2 2/+) [9] develop
subcutaneous fibromas or angiofibromas with associated calcifica-
tions [29], there has not been a mouse model that recapitulates the
SCO found in AHO in humans until now. We found that our
Gnas
E12/+ mice developed extensive and progressive ossifications,
thereby differing from the lesions reported in Gnas
E2 2/+ mice
which had no evidence of bone formation. In our Gnas
E12/+ mice,
lesions were very rarely found in the dermis and subcutis of 3
month old mice but were very common in 12 month old mice
[3,10,24]. Because palpable ossifications in AHO patients
frequently increase in number and size with age [3], we
investigated this in our Gnas
E12/+ mouse knockout model and
found that this was recapitulated. From analyses of mice at 3
months, 6 months, 9 months, and 12 months, it is clear that SCO
increase in number and size based on radiographic imaging,
although it is possible that the number of SCO are instead
constant, with the rapidity of growth differing among the lesions.
Computerized tomography verified that these lesions were
restricted to the subcutaneous layer and confirmed that the lesions
are much less apparent in younger mice. Alizarin Red and von
Kossa stains were positive for mineral deposits in the areas
surrounding hair follicles at 12 months of age, and many of these
areas contained bone marrow elements consistent with true bone
formation. This was further confirmed through in situ hybridiza-
tion with probes encoding osteonectin and osteopontin.
Male mice with inheritance of the mutant Gnas allele had more
severe and widespread heterotopic bone in the subcutaneous
tissue than female mice. The lesions in the female mice often
resembled precursors of bone consistent with osteoid in the
dermis located in the immediate perifollicular areas. The male
Figure 7. In situ hybridization analysis of dermal heterotopic bone using probes to markers of osteogenesis. Nonisotopically labelled
osteonectin-specific and osteopontin-specific probes hybridized with cells located in and directly adjacent to foci of dermal heterotopic bone in the
mice (no counterstain). Scale bars A, B, C=50 mm; D, E, F=10 mm.
doi:10.1371/journal.pone.0021755.g007
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ate the ossification process or estrogen may impair this process.
Interestingly, this gender difference has been reported by several
human case series in the literature discussing the formation of
heterotopic ossifications after surgery [30–34]. The predomi-
nance in males was reported to be 2–3 times that in females after
surgery [35]. Current analyses are underway to investigate
whether the male predominance of SCO formation holds true in
patients with AHO. Investigation of our mouse model could
provide important insight into possible hormonal impacts on the
development of heterotopic ossifications and whether hormonal
manipulation could aid in prevention, amelioration, and/or
treatment of ossification formation.
Although the SCO can occur spontaneously, we have found
that in AHO there is a subset of ossifications which occur in areas
of pressure and trauma, not only in our patients but also in our
mouse model of AHO. Physical examinations of our mice revealed
that areas of pressure/trauma such as foot pad lesions and ear tag
sites were prone to development of ossifications which occurred
more prevalently in males when examined at 12 months of age.
This is consistent with the post-operative surgical data in patients
as cited previously.
There were no differences in frequency and histological
appearance of murine SCO lesions caused by Gnas exon 1-
disruption of the maternal versus paternal allele. These findings in
patients and our genetically manipulated mice thus make it likely
that haploinsufficiency, rather than imprinted Gas expression in
an as-of-yet undefined osteogenic precursor, leads to the
development of these lesions; these findings are consistent with
non-imprinted expression of Gas in fibroblasts, chondrocytes, and
bone cells [28,36–39].
The ossifications appear to originate near the hair follicle. We
found extensive areas consistent with heterotopic bone formation
located in perifollicular areas in the dermis. There is evidence
demonstrating that hair follicle stem cells can differentiate into
several cell types including osteogenic lineages [40], thereby
raising the possibility that these hair follicle stem cells are
progenitors of osteogenesis in the skin. Hair follicle differentiation
is tightly controlled by complex pathways involving BMP’s and
Wnt signaling [41–43]. In addition, PTH/PTHrP has been
demonstrated to be involved in hair follicle development and the
modulation of pathways in both skin and hair follicle cells, thereby
implicating a potential role of Gas in this process [44–46].
There is also evidence that mesenchymal stem cells may
differentiate into osteogenic lineages. Human mesenchymal stem
cells treated with osteogenic medium revealed that knock-down of
Gas with antisense oligonucleotides induced expression of Cbfa1
and increased osteoblastic determination [47]. Recent data have
implicated vascular endothelial cells as multipotent stem-like cells
with osteogenic potential, thereby raising the possibility of
endothelial cells in the perifollicular areas of the dermis being a
possible osteogenic cell precursor [48]. Further studies to
determine the cell-type of origin of the heterotopic bone will be
crucial in understanding the etiology of the formation of SCO in
AHO.
Conclusion
Our mouse model of AHO replicates the human disorder
closely, both phenotypically and hormonally [10], and is the first
mouse model to exhibit SCO. Importantly, our findings
demonstrate that the Gnas exon 1-disrupted mouse model faithfully
recapitulates the development of subcutaneous ossifications
observed in PHP1a and PPHP patients. In patients with AHO,
the ossifications lead to pain and impairment in activities of daily
living. There is no effective treatment, and removal of the lesions is
often followed by recurrence. Hence, we believe that this mouse
model is an ideal system in which to test therapeutic strategies to
prevent or limit the growth of ossifications and consequently
decrease a source of significant morbidity in patients with AHO
and other disorders involving heterotopic bone formation.
Additionally, the Gnas exon 1-disrupted mouse model represents
a valuable tool to elucidate further the molecular and cellular
mechanisms involved in ectopic bone formation, as well as the
regulatory mechanisms important for bone formation in general.
Author Contributions
Conceived and designed the experiments: ELGL. Performed the
experiments: ELGL DLH SE YW. Analyzed the data: ELGL DLH SE
HJ. Contributed reagents/materials/analysis tools: ELGL DLH. Wrote the
paper: ELGL DLH. Helped with editing of manuscript: HJ MAL WS.
Figure 8. The ossifications appear to originate in the perifol-
licular areas. Ossifications are emanating near the hair follicle both
with hematoxylin and eosin staining (A) as well as Alizarin Red staining
(B). Scale bar=50 mm.
doi:10.1371/journal.pone.0021755.g008
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